Clinical trials
Observational Hearing Loss, Sudden trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Unknown status | 5 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tel-Aviv Sourasky Medical Center | 2 |
| Carmel Medical Center | 1 |
| Dan Bing | 1 |
| Eye & ENT Hospital of Fudan University | 1 |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1 |
| Hopital Lariboisière | 1 |
| Johns Hopkins University | 1 |
| Peking University People's Hospital | 1 |
| Sun Yuting | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hearing Loss, Sudden | 14 |
| Hearing Loss | 3 |
| Hearing Loss, Sensorineural | 2 |
| Labyrinthitis | 2 |
| Cochlear Diseases | 1 |
| Hearing Loss, Unilateral | 1 |
| Ischemia | 1 |
| Labyrinth Diseases | 1 |
| Meniere Disease | 1 |
| Thrombophilia | 1 |
Trials
Showing 26 to 14 of 14. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.